4.18

6.07% -0.27

Recursion Pharmaceuticals Inc (RXRX)

Overview News Price History Option Chain Financials Why RXRX Down? Discussions Forecast

Recursion Pharmaceuticals Inc stock is traded at $4.18, with a volume of 20.45M. It is down -6.07% in the last 24 hours and down -26.92% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Previous Close:

$4.45

Open:

$4.35

24h Volume:

20.45M

Relative Volume:

1.01

Market Cap:

$1.67B

Revenue:

$64.60M

Net Income/Loss:

$-377.75M

P/E Ratio:

-2.6968

EPS:

-1.55

Net Cash Flow:

$-335.64M

1W Performance:

+2.45%

1M Performance:

-26.92%

6M Performance:

-40.88%

1Y Performance:

-52.87%

1-Day Range:

$4.11

$4.36

1-Week Range:

$4.10

$4.69

52-Week Range:

$3.79

$12.36

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name

Recursion Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(385) 269-0203

Address

41S RIO GRANDE STREET, SALT LAKE CITY

Employee

800

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RXRX's Discussions on Twitter

Compare RXRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RXRX Recursion Pharmaceuticals Inc	4.18	1.66B	64.60M	-377.75M	-335.64M	-1.55
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight
Mar-16-23	Initiated	Needham	Buy
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-21	Initiated	Berenberg	Buy
May-11-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Goldman	Neutral
May-11-21	Initiated	JP Morgan	Neutral
May-11-21	Initiated	KeyBanc Capital Markets	Overweight
May-11-21	Initiated	SVB Leerink	Outperform

View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

May 30, 2025

Recursion to Participate in Upcoming Investor Conferences - FinancialContent

May 30, 2025

Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey

May 30, 2025

Did Jim Cramer Nail or Miss These 11 Stock Predictions? - Insider Monkey

May 30, 2025

May 29, 2025

Bank of America Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX) - The Globe and Mail

May 29, 2025

(RXRX) Trading Signals - news.stocktradersdaily.com

May 29, 2025

May 27, 2025

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? - Zacks Investment Research

May 27, 2025

May 26, 2025

3 Monster Stocks to Hold for the Next 10 Years - Mitrade

May 26, 2025

3 Monster Stocks to Hold for the Next 10 Years - The Motley Fool

May 26, 2025

May 24, 2025

Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales - Yahoo Finance

May 24, 2025

May 18, 2025

(RXRX) Technical Data - news.stocktradersdaily.com

May 18, 2025

May 15, 2025

Transcript : Recursion Pharmaceuticals, Inc. Presents at 53rd Annual JPMorgan Global Technology, Media and Communications Conference, May-15-2025 10 - marketscreener.com

May 15, 2025